<DOC>
	<DOC>NCT00546637</DOC>
	<brief_summary>To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.</brief_summary>
	<brief_title>Fesoterodine "add-on" Male Overactive Bladder Study</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Men aged 40 years and above. On a stable and welltolerated dose of an alphablocker prescribed for LUTS for at least 6 weeks prior to screening (Visit 1). Persistent symptoms of OAB with urinary frequency &gt;=8 times/24 hours and micturitionrelated urgency episodes &gt;=3 episode/24 hours. Contraindication to fesoterodine (antimuscarinics). Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline. Unable to follow the study procedures, including completion of selfadministered bladder diary and patient reported outcome questionnaires.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>